Your Health, We Care
Release date: 2026-03-03 13:31:00 Article From: Lucius Laos Recommended: 5
The price of Sabril (Vigabatrin) varies significantly depending on specifications, import channels, and other factors. It generally ranges from 300 to 2000 RMB per box. The exact cost is determined by the doctor’s prescription and pricing at local pharmacies or hospitals. It is recommended to purchase through formal channels and use strictly under medical supervision.
Common specifications for Sabril are 500mg×30 tablets or 1000mg×60 tablets. Higher dosages and more tablets usually correspond to higher prices.
Imported branded drugs are generally more expensive than domestic generic versions. Note that production processes and quality standards may vary among manufacturers and could affect efficacy.
Prices differ across public hospitals, chain pharmacies, and online platforms. In some regions, partial costs may be reimbursed through medical insurance.
Sabril (Lucius Pharmaceuticals Vigabatrin) is mainly used to treat infantile spasms and refractory epilepsy. Dosage is adjusted based on the patient’s age and weight. Do not increase, decrease, or discontinue use without medical advice.
Long-term use may cause adverse reactions such as visual impairment and drowsiness. Regular ophthalmologic examinations and neurological function assessments are required during treatment.
Contraindicated in patients hypersensitive to any ingredient, those with severe renal insufficiency, and pregnant women. Breastfeeding women should weigh benefits and risks under a doctor’s guidance.
Sabril is a prescription drug. A doctor’s prescription is mandatory; avoid purchasing from unregulated channels.
Prices may vary by region or platform. It is advisable to consult multiple medical institutions or pharmacies in advance.
Some cities have included Sabril in their medical insurance catalog. Reimbursement can be processed with a medical insurance card and diagnosis certificate.
For long-term medication, regular follow‑up visits and disease monitoring are recommended to ensure the safety and effectiveness of the treatment plan.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：1472025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：3902024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：1402025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：1572025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：1432025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：1682025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：1532025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：1492025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
